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Abstract
Background: The purpose of this study is to report the prevalence, etiology, treatment and outcomes of
neovascular glaucoma (NVG) in a tertiary care ophthalmic center in China.
Methods: Medical records of patients diagnosed as NVG at the Wenzhou Medical University between 2003 and
2014 were reviewed. Success was defined as IOP between 6 and 21 mmHg without topical or systemic glaucoma
medications with retention of presenting visual acuity (VA).
Results: NVG was diagnosed in 483 of 8306 (5.8 %) of all glaucoma patients. Etiology is reported for all 310 eyes
of 284 patients managed in the department. Interventions depended on insurance as well as personal finances;
outcomes are reported for the 149 eyes of 138 patients with complete data that met follow up requirements.
Diabetic retinopathy (DR,39.7 %) was the major cause of NVG. Kaplan Meier survival analysis showed a success rate
of 84.8 % at 1 year, 47.5 % at 3 years and 21.9 % at 5 years. Major interventions included glaucoma drainage device
(GDD) in 103 eyes and trans-scleral cyclophotocoagulation (TSCPC) in 22 eyes. Complications were more common
in the GDD group.
Conclusions: NVG comprised 5.8 % of glaucoma patients seen in a tertiary Chinese hospital. DR was identified as
the commonest cause and probably reflects the increasing prevalence of diabetes in China. Surgical interventions
were partly determined by insurance status and personal finances. GDD was the commonest surgical intervention
used and also had the most complications.
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Background
Neovascular glaucoma (NVG) is a secondary, refractory
condition that accounts for 0.7–5.1 % of glaucoma in an
Asian population [1, 2]. The condition is secondary to
obstruction of the trabecular meshwork by neo-vascular
membrane that develops in response to retinal ischemia
[3, 4]. Current surgical options for intraocular pres-
sure (IOP) control in NVG comprise augmented tra-
beculectomy, glaucoma drainage devices (GDD) and
cyclophotocoagulation (CPC) while prognostic factors
include young age, previous vitrectomy and post-
surgery complications [4–6]. Recent prospective data
on the management of refractory glaucoma from
China reported GDD as safe and effective for some of
the conditions but with a relatively poor outcome in
NVG [7]. Late presentation and loss of follow up are
additional challenges for the management of NVG in
China [8].
There is paucity of data from China relating the causes
and management of NVG. The objective of this study is
to report the causes, management and outcomes of NVG
in a tertiary facility in China.
Methods
The study was approved by the ethics committee of the
Wenzhou medical university. As this was a retrospective
study with de-identified data informed consent was not
required. The records of all patients diagnosed as NVG
between June 2003 and March 2014 at the eye hospital
of Wenzhou Medical University, Wenzhou, China were
reviewed. The diagnosis of NVG was based on an IOP >
21 mmHg on applanation tonometry associated with neo-
vascularization of the iris and/or angle of the anterior
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chamber detected by slit lamp bio-microscopy and gonio-
scopy [9]. All patients with NVG treated in our hospital
were investigated to determine the cause. Other data
extracted from the records included age, gender, affected
eye, visual acuity(VA), lens status, IOP, number of glau-
coma medications used at presentation and at last visit,
types of intervention, history of previous intraocular sur-
gery, use of anti-VEGF agents and post operative compli-
cations. Etiology of NVG was reported for all patients
managed in the hospital. Patients with a follow up of less
than 6 months were excluded, as were those without IOP
and VA data at the final visit.
All patients received treatment for the underlying
cause as well as medical treatment for control of IOP.
Surgery was undertaken if further IOP lowering was
deemed necessary either for retention of vision or for
comfort. The overall management however depended
not only on surgeon preference but also on insurance
cover as well as capacity to pay. While 95 % of our
patients had medical insurance, reimbursement is not
uniform and payment for prosthesis like GDD is usual.
Surgery if indicated was undertaken by one of 5 sur-
geons. For patients with useful vision, most surgeons
preferred GDD as the first surgical option. Trabeculect-
omy was offered for such patients if economic factors
precluded the use of a GDD, while trans-scleral cyclo-
photocoagulation (TSCPC) was generally offered those
without useful vision. Endoscopic cyclophotocoagulation
(Endo-CPC) was introduced in our hospital in 2006 and
was combined with cataract surgery/vitrectomy or used
in isolation for refractory NVG in some pseduophakic
eyes. Anti-vascular endothelial growth factor (anti-
VEGF) became available in the clinic from 2008 and was
used on a case-by-case basis determined primarily by
insurance cover and affordability.
All GDD surgery was performed using Ahmed im-
plants (New World Medical, Inc., Rancho Cucamonga,
CA, USA). The surgical technique used for GDD and
trabeculectomy were similar to that described in the lit-
erature [10, 11]. All trabeculectomies were performed
with adjunctive mitomycin C, but the decision to use
mitomycin with GDD was made by the individual sur-
geon. TSCPC was performed using the G probe with the
diode laser (Iridex Corporation, Mountain View, CA,
USA); Endo-CPC; was undertaken with the Endo-OPTIKS
machine (Endo-OPTIKS, Little Silver, NJ, USA). The tech-
nique of TSCPC and Endo-CPC used was similar to that
described [12, 13]. For TSCPC, three to four quadrants
were treated with the G probe with about 20 spots avoid-
ing the 3 and 9 o’clock positions with parameters adjusted
to avoid a ‘pop’. For Endo-CPC about 200 degrees of
ciliary processes were coagulated.
Success was defined as an IOP between 6 and 21 mmHg
without topical or systemic glaucoma medications with
retention of presenting VA; this visual criteria was applied
to patients with a VA of light perception or better [5].
Snellen’s VA was converted to the logarithm of the min-
imal angle of resolution (LogMAR) for analysis. An im-
provement or decrease in visual acuity was defined as a
change of two or more lines on the LogMAR scale. Log-
MAR values for low vision were defined as follows: count-
ing fingers (CF) =2.3; hand motions (HM) =2.6; light
perception (LP) =2.9; and no light perception (NLP) =4
[14]. For those with low vision, a difference of one low
vision category post-surgery was considered as change.
Patients with incomplete data (lack of IOP and VA) and
follow up less than 6 months were excluded from the
analysis of outcomes.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware version 15.0 (SPSS, Inc., Chicago, IL) and p < 0.05
was considered significant. Normality of variables was
ascertained using Kolmogorov-Smirnov tests. Continuous
normally distributed data were presented as mean ± stand-
ard deviation; proportions (%) were used to describe cat-
egorical variables while non-normal distribution variables
were presented as median (interquartile range). The
paired student t-test and Wilcoxon signed-rank test was
performed to compare the IOP and mean number of
anti-glaucoma medications at presentation and at last
visit respectively. Kaplan Meir survival analysis was
used to report success rates. Cox’s proportional hazards
regression model [odds ratio (OR) with 95 % confidence
interval (CI)] was used to report the association of poten-
tial prognostic factors: age, binocular involvement, lens
status, previous intraocular surgery (vitrectomy or cataract
surgery), systemic diseases, use anti-VEGF for underlying
cause, history of PRP and influence of postoperative
complications.
Results
NVG was diagnosed in a total of 483 (5.8 %) of the 8306
glaucoma patients seen during the study period. 199
patients elected to seek care elsewhere while 284 were
investigated and managed at the Wenzhou medical uni-
versity eye department. Etiology of NVG was established
and reported for these 284 patients. After excluding 14
patients lacking IOP or VA data at their last visit and
132 patients with less than 6 months follow up, 149 eyes
of 138 patients (85 males and 53 females) were available
for reporting interventions and outcomes.
Patient demographics are shown in Table 1. All
patients were Han-Chinese. The mean age was 64.2 ±
14.0 years (range, 10–94 years) and the median follow-
up 18.5 months (range, 6.07–103.8 months). There were
105 phakic (70.5 %), 11 aphakic (7.4 %) and 33 pseudo-
phakic (22.1 %) eyes. The causes of NVG are listed in
Liao et al. BMC Ophthalmology  (2016) 16:14 Page 2 of 6
Table 2. Diabetic retinopathy (123/310 eyes, 39.7 %) was
the commonest followed by CRVO (66/310 eyes, 21.3 %).
The primary cause could not be determined in 59 eyes
(19.0 %). 26 patients had bilateral NVG; 15 of these
patients presented with bilateral NVG while 11 were
diagnosed in the fellow eye after 1 to 16 months. 20/26
(76.2 %) cases with bilateral NVG were caused by DR, two
were due to bilateral CRVO, one had bilateral uveitis, one
was ascribed to bilateral BRVO, one was caused by the
ocular ischemia syndrome while the cause in one bilateral
case remained unknown.
In eyes with presenting VA of LP or better (93 eyes
of 86 patients), VA was retained in 34 eyes (36.6 %),
decreased in 38 eyes (40.9 %) and improved in 21
(22.6 %) eyes. Deterioration of vision to NLP occurred in
16/93 (17.2 %) eyes. Two of these 16 eyes had useful VA
(LogMAR= 1) prior to surgery. One case was caused by
severe DR while the other was caused by BRVO. Both
were managed with a GDD; one case developed retinal
detachment.
Of the 149 eyes, two developed phthisis bulbi and 5 re-
quired enucleation. Excluding these 7 eyes, IOP decreased
from a mean (± SD) of 43.5 ± 10.9 to 19.0 ± 11.4 mmHg
(p = 0.000). The number of glaucoma medications was
reduced from 2 (interquartile range =3) to 0 (interquartile
range = 1.5) after interventions (p = 0.000)
Kaplan-Meier survival analysis is shown in Fig. 1. Suc-
cess was achieved in 84.8 % at 1 year, 47.5 % at 3 years
and 21.9 % at 5 years. Six eyes that required combinations
of GDD, TSCPC or trabeculectomy were excluded from
this analysis (3 eyes that underwent TSCPC followed by
GDD or Trabeculectomy and 3 that required TSCPC
following GDD). Of the remaining 143 eyes, 103 eyes
underwent GDD, 22 eyes were treated with TSCPC, 7 eyes
had trabeculectomy, 3 eyes underwent Endo-CPC and 8
eyes underwent combined surgery. Table 3 details the
treatment modalities and their outcomes. Age, lens status,
the use of anti-VEGF, postoperative complications, PRP,
prior-intraocular surgery did not have a statistically signifi-
cant influence on outcome (Table 4).
Postoperative complications are summarized in Table 5.
Shallow anterior chamber was the commonest com-
plication (12/143, 8.4 %) followed by hypotony (8/143,
5.6 %). Tube-related complications included occlusion/
Table 1 Demographic Data
Clinical characteristics of eyes with neovascular glaucoma (N = 149)
Age in years (range) 64.2 ± 14.0 (10–94)
Eyes (%)
Right 76 (51.0 %)
Left 73 (49.0 %)
Gender (%)
Male 85 (61.6 %)
Female 53 (38.4 %)
Lens (%)
Phakic 105 (70.5 %)
Aphakic 11 (7.4 %)
Pseudophakic 33 (22.1 %)
Presenting Vision
Improvement VA 21 (22.6 %)
Unchangeda 34 (36.6 %)
Decrease VA 38 (40.9 %)
Decrease to NLP 16 (17.2 %)
Previous VA = 1 2
Previous VA = CF 1
Previous VA = HM 6
Previous VA = LP 7
IOP at presentationb 43.5 ± 10.9
IOP at final follow-upb 19.0 ± 11.4
Glaucoma medications
Median at presentation (IQR) 2 (3)
Median at final follow up (IQR) 0 (1.5)
Median interval of follow up in months (IQR) 18.5 (17.6)
History of intraocular surgery 54 (36.2 %)
Complications 38 (25.5 %)
Enucleation (%) 5 (3.4 %)
Hypotony (%) 8 (5.4 %)
IOP intraocular pressure, VA visual acuity, IQR interquartile range
a56 eyes with NLP at presentation were excluded
b5 enucleation and 2 phthisis bulbi excluded
Table 2 Etiological Factors Associated with NVG








Ocular ischemia syndrome 7 (2.3)
Uveitis 6 (1.9)
Trauma 13 (4.2)
Surgical causes 3 (1.0)
Radiation 1 (0.3)
Unknown 59 (19.0)
DR diabetic retinopathy, CRVO central retinal vein occlusion, CRAO central retinal
artery occlusion, BRVO branch retinal vein occlusion, RD retinal detachment
aIncluding Coat’s exudative retinopathy (4), Ischemic optic neuropathy (2),
Hypertensive retinopathy (1) and Persistent Hyperplastic Primary Vitreous (1)
and Eales’ disease (1)
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displacement of the tube and occurred in 2 eyes. Most
complications occurred in the GDD group.
Discussion
A survey by the Beijing union medical college hospital
and WHO in 1996 reported that the prevalence of
secondary glaucoma in the population over the age of
50 years was 0.12 % and accounted for 5.9 % of all glau-
coma [15]. NVG per se was not reported, but as it is a
secondary glaucoma, we can infer that the proportion of
NVG in that survey was lower than 5.9 %. NVG was
diagnosed in 5.8 % of 8306 glaucoma patients seen in
our tertiary hospital. This is similar to the 6.7 % of 1232
Chinese subjects diagnosed as glaucoma in a population
based survey in Singapore [16]. Although it cannot really
be compared to population-based data, Our data pro-
vides the prevalence of NVG in a tertiary eye hospital in
China.
DR (39.7 %) followed by CRVO (21.3 %) was the major
cause of NVG in this series. While the etiology could
only be determined for the 284 patients who elected to
continue their care in our center, the pattern is consistent
with reports from other countries [17–19]. A recent hos-
pital based report from China provides conflicting results:
CRVO (39.2 %) was reported as the commonest cause in
120 NVG eyes [20]. Diabetes, a major cause of NVG has
Fig. 1 Kaplan-Meier survival curve of treatment outcomes in all 138 NVG patients (149 eyes). Censored data relates to the ones who had not
observed failure at that time (including missing data)
Table 3 Treatment and results (N = 143 eyes)a
Treatments[N(%)] No. cases Complete success rate Decreased VA The percentage of IOP reduction
TB 7 (4.9 %) 4 (57.1 %) 2 (28.6 %) 70.0 %
GDD 103 (72.0 %) 46 (32.2 %) 35 (34.0 %) 54.8 %b
TSCPC 22 (15.4 %) 7 (31.8 %) 4 (18.2 %) 66.8 %c
Endo-CPC 3 (2.1 %) 0 3 (100 %) 17.2 %d
Combined surgery 8 (5.6 %) 4 (50.0 %) 1 (12.5 %) 61.1 %
Vitrectomy & GDD 3 1 0 48.2 %
Cataract & GDD 3 3 0 73.6 %
Cataract & Endo-CPC 2 0 1 60.5 %
TB trabeculectomy, GDD glaucoma drainage devices, TSCPC trans sclera cyclophotocoagulation, Endo-CPC endoscopic cyclophotocoagulation
a6 eyes treated with multiple operations excluded
bGDD group excludes 1 enucleated eye
cTSCPC group excludes 3 enucleated eyes and 1 with phthisis bulbi
dEndo-CPC group excludes 1 eye with phthisis
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increased in China over the years and has a current
reported prevalence of 23 %, affecting an estimated 92.4
million adults in the mainland [21]. Our data seems to
suggest a change in etiology of NVG that is likely linked
to the increasing prevalence of diabetes in China. Lack of
data and the retrospective nature of the study contributed
to our inability to identify the cause in 19 % of cases.
VA results were sobering. Acuity was poor to start
with and could only be preserved or improved in 59 %
of cases while 41 % worsened, with 16 eyes deteriorating
to no light perception. Improvement in vision occurred
in 21/93 eyes (90 % due to resolution of corneal edema,
hyphema and/or vitreous hemorrhage). GDD was the
commonest surgical intervention used and also had the
most complications. Interventions in our hospital de-
pend on surgeon preference and experience as well as
cover by medical insurance. GDD (103/143, 70.2 %) was
the first option for controlling IOP in NVG patients with
potential for vision. TSCPC was the second choice (22/
143, 15.4 %) and tended to be used in those with a poorer
prognosis.
Kaplan-Meier survival analysis showed a 84.8 probability
of success at 1 year, 62.6 % at 2 years and 21.9 % at 5 years.
Nakatake, etc. found that success rate of primary trabecu-
lectomy (with or without anti-VEGF) prior to surgery was
70.9 % after 1 year, decreasing to 60.8 % in 2 years [6]. A
recent report from Japan showed that the success rate was
higher (83 % at 3 years) if trabeculectomy was preceded
by a preoperative intravitreal injection of Bevacizumab
[22]. A publication from Korea reported a success rate of
79 % at 1 year decreasing to less than 60 % at 2 years [23].
As our numbers were small we could not report the out-
comes for each intervention separately and our results
cannot be easily compared to previous reports. However
our findings do reflect the reality of management, out-
come and poor follow up even in a tertiary care center
China. The high success rate at 1 year could be due to in-
clusion criteria, exclusion of patients with follow up less
than 6 months as well as loss to follow up.
Cox proportional hazards model showed that factors
like systemic disease, lens status, complications, anti-
VEGF agents, PRP and prior-intraocular surgery did
not influence the treatment outcome of NVG, but
our numbers are small. While, anti-VEGF agents may
be beneficial for the management of NVG reducing
the need for glaucoma surgery and decreasing compli-
cations in eyes with neovascular glaucoma, the
addition of intravitreal bevacizumab did not seem to
increase the success rate in previous studies [24, 25].
All cases that required PRP underwent the procedure,
but its influence on incidence of NVG is not clear
[26, 27]. While PRP eliminates the stimulus for neovascu-
larization it does not affect existing peripheral anterior
synechiae (PAS) [28].
The complications encountered following intervention
in this study were those usually reported after such
interventions. Shallow anterior chamber was the most
frequent early complication (8.5 %), while hypotony was
the most frequent late complication (5.6 %). The ex-
treme low complication rate could not compare with
previous reports from Asian directly [6, 29]. It is very
likely that the discrepancy between complication rates in
our study and others are related to the poor follow up
rates in the current study (i.e. patients with mild compli-
cations mostly like lost follow-up) and some data unavail-
able in this retrospective study. Given the limitations of
sample size we too found that larger IOP reductions could
be achieved with tube surgery compared to TSCPC but
the postoperative complications were higher and included
some sight threatening ones [30]. Although we did not
encounter any endophthalmitis, phthisis and severe pain
requiring enucleation occurred in 5 patients, three of
those in the TSCPC group.
The limitations of the study include the retrospective
design, exclusion of a large number of cases due to lack
of follow up and lack of data as well as the lack of stan-
dardized management. The lack of a preferred practice
Table 4 Prognostic factors
Parameters P Odds ratio 95 % confidence interval
Age 0.85 1.07 0.53–2.16
Binocular 0.34 1.36 0.72–2.56
Lens status 0.99 1.00 0.72–1.39
Prior surgery 0.78 1.10 0.59–2.02
Hypertension 0.34 1.28 0.77–2.11
Diabetes 0.18 0.69 0.40–1.19
Anti-VEGF 0.32 1.79 0.58–5.56
Complications 0.30 0.78 0.48–1.25
PRP 0.43 1.22 0.74–2.01
Table 5 Postoperative complications (N = 143 eyes)a
Complications Number (%) Group with highest
incidence
Hyphema 4 (2.8) GDD (4)
Shallow anterior chamber 12 (8.4) GDD (10)
Choroidal detachment 2 (1.4) GDD (2)
Ciliary body detachment 4 (2.8) GDD (4)
Tube related complicationsb 2 (1.9) -
Bleb-related complicationsc 3 (2.6) GDD (3)
Hypotony 8 (5.6) GDD (4)
Endophthalmitis 0 -
GDD glaucoma drainage devices
a6 eyes treated with multiple operations were excluded
b103 eyes treated with GDD were analyzed
c22 eyes treated with TSCPC, 3 with Endo-CPC and 2 with cataract & Endo-CPC
were excluded
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or standardized regime also meant that the numbers for
some interventions were too small to conduct any
analysis. The fact that the management is affected by in-
surance status and personal finances made it difficult to
create a protocol or standardize procedures, but this as
well as poor follow up is the reality in China. This case
series does however demonstrate the changing etiology
of NVG in China, has the longest follow-up of NVG in
an Asian population and reflects the reality of management
in China.
Conclusion
Diabetic retinopathy was the commonest detected cause
of NVG encountered in a tertiary hospital in China.
Cases present late, follow up is poor and management is
partly determined by surgeon preference, insurance
cover and personal finances. The increasing prevalence
of diabetes in China will likely lead to a higher incidence
of NVG and other related complications.
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